David A. Siegel Rain Therapeutics Inc. Call Options Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding RAIN
# of Institutions
3Shares Held
122KCall Options Held
0Put Options Held
0About Rain Therapeutics Inc.
- Ticker RAIN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,837,400
- Description
- Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...